lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
4,681 rows where filing_period = "fourth_quarter" and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3477074 | REPUBLIC CONSULTING, LLC dd0fed67-4de3-46db-b1c6-caf7dfa73d43 | Q4 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2025 | fourth_quarter | PHA | monitor health data policy. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-12-20T11:23:12-05:00 | |
| 3477490 | TAUZIN STRATEGIC NETWORKS 02acdad5-c2d5-41b7-98a0-aa060dddeb3e | Q4 | TAUZIN STRATEGIC NETWORKS | 400786367 | RAZORMETRICS | 2025 | fourth_quarter | PHA | Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 37500 | 0 | 0 | 2026-01-01T05:43:49-05:00 | |
| 3478183 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 0827057e-ee14-443f-b4f5-8c57f9602a7f | Q4 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | CHILDREN'S NATIONAL MEDICAL CENTER | 2025 | fourth_quarter | PHA | Health-related issues including reimbursement, research, public-health & clinical care. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2026-01-05T13:29:03-05:00 | |
| 3478331 | MCDERMOTT+ LLC cf1bc6e4-3bcf-406d-8f98-8f8139924aa0 | Q4 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2025 | fourth_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in thefederal discount drug purchasing program. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-05T15:24:45-05:00 | |
| 3478477 | AMERICAN PHARMACISTS ASSOCIATION 4d31eee0-6423-40e8-9da7-4e5abff32881 | Q4 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2025 | fourth_quarter | PHA | PBM reform Pharmacist payment reform | HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2026-01-06T09:20:40-05:00 | |
| 3478501 | AMERICAN COLLEGE OF CLINICAL PHARMACY fdc9720a-30cd-4f38-b544-e86228eaa7d1 | Q4 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2025 | fourth_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2026-01-06T10:19:08-05:00 | |
| 3478970 | NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION 5f32f3a5-c5cc-4825-9bb4-29bd73e9fc1d | Q4 | NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION | 27786 | NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION | 2025 | fourth_quarter | PHA | 340B | Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2026-01-07T08:14:41-05:00 | ||
| 3479324 | MARBLE ARCH 14138636-7e81-46a8-bdbc-42226aa90f68 | 4T | MARBLE ARCH | 401109131 | ON DEMAND PHARMACEUTICALS | 2025 | fourth_quarter | PHA | Issues relating to securing the domestic pharmaceutical supply chain, ensuring reliable access to essential medications, and manufacturing of high-quality generic drugs in America. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 1 | 2026-01-07T17:19:36-05:00 | |
| 3479617 | MANATOS & MANATOS 533b55c5-1fd2-41bc-b97f-cb203e3bc503 | Q4 | MANATOS & MANATOS | 23634 | VANDA PHARMACEUTICALS INC | 2025 | fourth_quarter | PHA | FDA approval of specific medical drugs | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2026-01-08T13:07:59-05:00 | ||
| 3480028 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 22708aca-e82a-4f53-a9d6-a2b8858673e2 | Q4 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2025 | fourth_quarter | PHA | 340b | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30780 | 0 | 0 | 2026-01-09T08:46:09-05:00 | |
| 3480062 | WAKEFERN FOOD CORP. b21c23dc-74a7-469d-af8b-991c999f46e6 | Q4 | WAKEFERN FOOD CORP. | 400588798 | WAKEFERN FOOD CORP. | 2025 | fourth_quarter | PHA | The PBM Reform Act (H.R. 4317) PBM Price Transparency and Accountability Act (S. 3345) | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2026-01-09T10:27:22-05:00 | ||
| 3480137 | INDEPENDENT PHARMACY COOPERATIVE dac2a2f8-d35e-4305-982b-fe7d5e6ded32 | Q4 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2025 | fourth_quarter | PHA | IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports S. 882 Patients Before Middlemen Act IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "The Ensuring Community Access to Pharmacists Services (ECAPS) Act IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) CMS Plan Year 2027 Medicare Drug Price Negotiation Program list of negotiated drug prices and process for negotiations. IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 40000 | 0 | 0 | 2026-01-09T12:13:13-05:00 | |
| 3480243 | PENN AVENUE PARTNERS aec8b3de-3986-4f25-96ba-61868b50828a | Q4 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2025 | fourth_quarter | PHA | Regulatory and legislative issues impacting Alkermes. Appropriations. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 80000 | 0 | 0 | 2026-01-09T15:07:43-05:00 | |
| 3480381 | TRUSYNERGY d3750953-345a-45d3-a4da-197d55f328b2 | Q4 | TRUSYNERGY | 401107715 | BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) | 2025 | fourth_quarter | PHA | Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher; MFN drug pricing; tariffs | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2026-01-09T17:12:20-05:00 | |
| 3480890 | AEGIS LLC d035b28c-6490-425c-a5be-aed0ccb5c5e5 | Q4 | AEGIS LLC | 401108688 | TRIS PHARMA, INC. | 2025 | fourth_quarter | PHA | ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. Most-Favored Nation (MFN) International reference pricing. Make America Healthy Again (MAHA) Commission. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-12T08:03:03-05:00 | |
| 3480891 | AEGIS LLC e47ab4f3-7f0a-4ce0-8a0f-3b1534ad345b | Q4 | AEGIS LLC | 401108688 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 | fourth_quarter | PHA | Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. Most-Favored Nation (MFN) International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-12T08:04:18-05:00 | |
| 3480987 | BGR GOVERNMENT AFFAIRS 7b90e2c4-30e1-4951-8094-1189e016455a | Q4 | BGR GOVERNMENT AFFAIRS | 5357 | NEUROCRINE BIOSCIENCES, INC. | 2025 | fourth_quarter | PHA | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-12T09:25:50-05:00 | |
| 3480990 | BGR GOVERNMENT AFFAIRS 62a016bf-bf7b-4eb7-b4ff-ac1121b258fb | Q4 | BGR GOVERNMENT AFFAIRS | 5357 | WALGREEN CO. | 2025 | fourth_quarter | PHA | Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-12T09:31:19-05:00 | |
| 3480993 | BGR GOVERNMENT AFFAIRS 9338b96d-036e-45d3-81a9-75956aff15b6 | Q4 | BGR GOVERNMENT AFFAIRS | 5357 | WALGREEN CO. | 2025 | fourth_quarter | PHA | Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-12T09:35:02-05:00 | |
| 3481001 | VENABLE LLP 01a7e96e-3c80-4f7e-a8ff-588b68c288f3 | Q4 | VENABLE LLP | 39941 | MEDISCA INC. | 2025 | fourth_quarter | PHA | FDA policy; matters related to pharmacy compounding; trade issues related to compounding | 20000 | 0 | 0 | 2026-01-12T09:40:33-05:00 | ||
| 3481298 | NAVITUS HEALTH SOLUTIONS eb86b801-e6c8-4393-9fb6-bff1f0b52546 | Q4 | NAVITUS HEALTH SOLUTIONS | 401107191 | NAVITUS HEALTH SOLUTIONS | 2025 | fourth_quarter | PHA | Patients before Monopolies Act, Specialty pharmacy licensing and compensation | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,Treasury, Dept of | 30000 | 0 | 0 | 2026-01-12T12:17:15-05:00 | |
| 3481345 | MR. H.R. BERT PENA caa0d544-1c82-4dae-a4af-74c4fe556d3f | Q4 | MR. H.R. BERT PENA | 400323519 | MARGO RX LLC(DBA RICHARD'S PHARMACY) | 2025 | fourth_quarter | PHA | PBM issues | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2026-01-12T12:53:07-05:00 | ||
| 3481428 | PANNONE LOPES DEVEREAUX & O'GARA LLC a6f425f7-b7ba-40b7-997b-3c9d291ef73a | Q4 | PANNONE LOPES DEVEREAUX & O'GARA LLC | 401105501 | AMGEN | 2025 | fourth_quarter | PHA | Prescription drug pricing. | 9000 | 0 | 0 | 2026-01-12T13:25:33-05:00 | ||
| 3481477 | AMERICAN VETERINARY MEDICAL ASSOCIATION 2af7ca7e-d19d-4a09-ae19-7bf807b6bb4a | Q4 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2025 | fourth_quarter | PHA | Xylazine; Combating Illicit Xylazine Act (HR1266/S545); Controlled Substances used in veterinary medicine, Controlled Substances Act and regulations as related to veterinary medicine. Issues related to the FDA CVM. | HOUSE OF REPRESENTATIVES,SENATE | 170000 | 0 | 0 | 2026-01-12T13:47:13-05:00 | |
| 3481762 | SURESCRIPTS 3ec1af8d-e8bd-48c9-9a0a-e6928f8fdf90 | Q4 | SURESCRIPTS | 401109459 | SURESCRIPTS | 2025 | fourth_quarter | PHA | Efforts to advance health data interoperability; ensure technological advances in the pharmacy services sector, including electronic prescribing ofcontrolled substances, real-time pharmacy benefit information to patients and other stakeholders. Efforts to promote equitable community access to pharmacist services. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2026-01-12T16:32:00-05:00 | ||
| 3481788 | LMH STRATEGIC SOLUTIONS 11cebcd3-a9fb-4d47-9d87-3953b773f701 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | ACADIA PHARMACEUTICALS | 2025 | fourth_quarter | PHA | Prescription drug payment reform. Pharmaceutical supply chain. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-12T17:01:55-05:00 | |
| 3481791 | LMH STRATEGIC SOLUTIONS 91a353c0-6e17-46d5-a731-f0387c0656ba | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | ARDELYX, INC. | 2025 | fourth_quarter | PHA | Prescription drug payment reform. Pharmaceutical supply chain. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-12T17:03:31-05:00 | |
| 3481793 | LMH STRATEGIC SOLUTIONS 8fd0cf41-210c-47bb-8aa3-094f605335b9 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | AVADEL PHARMACEUTICALS, PLC | 2025 | fourth_quarter | PHA | Prescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act. VA Appropriations Request. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-12T17:04:12-05:00 | |
| 3481795 | LMH STRATEGIC SOLUTIONS 4d2468cd-555b-4903-bb86-1eb0021d71d8 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | BIOMARIN PHARMACEUTICAL, INC. | 2025 | fourth_quarter | PHA | Prescription drug payment reform. Pharmaceutical supply chain. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-12T17:04:38-05:00 | |
| 3481800 | LMH STRATEGIC SOLUTIONS f0febf15-8090-486e-a625-3783ef138997 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | EXELIXIS, INC. | 2025 | fourth_quarter | PHA | Prescription drug payment reform. Pharmaceutical supply chain. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-12T17:05:32-05:00 | |
| 3481803 | LMH STRATEGIC SOLUTIONS 5afde9cc-87fa-4028-ae28-2de655ac7e41 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | GLAXOSMITHKLINE LLC | 2025 | fourth_quarter | PHA | Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-12T17:06:04-05:00 | |
| 3481806 | LMH STRATEGIC SOLUTIONS 32e67921-e0e4-40b0-b92a-301199cef151 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | HARMONY BIOSCIENCES | 2025 | fourth_quarter | PHA | Prescription drug payment reform. Pharmaceutical supply chain. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-12T17:06:46-05:00 | |
| 3481810 | LMH STRATEGIC SOLUTIONS 773a78b3-3b10-4496-ab70-33514b821644 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | INCYTE CORPORATION | 2025 | fourth_quarter | PHA | Prescription drug payment reform. Pharmaceutical supply chain. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2026-01-12T17:07:22-05:00 | |
| 3481818 | LMH STRATEGIC SOLUTIONS 5d47fd68-f282-4fc5-902a-f13e887bf913 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | NEUROCRINE BIOSCIENCES, INC. | 2025 | fourth_quarter | PHA | Prescription drug payment reform. Pharmaceutical supply chain. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-12T17:08:57-05:00 | |
| 3481821 | LMH STRATEGIC SOLUTIONS 950226e1-17ef-40a7-8f8e-81acc47ac145 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 | fourth_quarter | PHA | Pharmaceutical Supply Chain. H.R.2213 - Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832 - EPIC Act of 2025. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-12T17:09:57-05:00 | |
| 3481823 | LMH STRATEGIC SOLUTIONS 242d5db5-fceb-4893-b92c-197974c6aada | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | REGENXBIO INC. | 2025 | fourth_quarter | PHA | Prescription drug payment reform. Pharmaceutical supply chain. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-12T17:10:57-05:00 | |
| 3481825 | LMH STRATEGIC SOLUTIONS 6cf5c685-f255-45d8-a87e-65fb77f03566 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | SAVARA INC. | 2025 | fourth_quarter | PHA | Monitor prescription drug payment reform. Monitor supply chain. | 30000 | 0 | 0 | 2026-01-12T17:11:29-05:00 | ||
| 3481830 | LMH STRATEGIC SOLUTIONS 015d438e-1b6d-4178-8019-9f4e63afd2d2 | Q4 | LMH STRATEGIC SOLUTIONS | 401108183 | TRAVERE THERAPEUTICS, INC. | 2025 | fourth_quarter | PHA | Monitored Most-Favored Nation (MFN). | 30000 | 0 | 0 | 2026-01-12T17:12:28-05:00 | ||
| 3481893 | BROYDRICK & ASSOCIATES ea88fcd0-8838-463a-acc0-6cbdaf959f8d | Q4 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2025 | fourth_quarter | PHA | Funding new drug for PTSD and COVID 19, BARDA appropriations. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2026-01-12T17:43:48-05:00 | |
| 3482098 | WAXMAN STRATEGIES 1917692d-8591-400c-a2f3-cdd7e9904a9e | Q4 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2025 | fourth_quarter | PHA | Issues affecting the 340B drug pricing program; Appropriations for 340B program. | HOUSE OF REPRESENTATIVES,SENATE | 39000 | 0 | 0 | 2026-01-13T09:59:38-05:00 | |
| 3483004 | VERTEX PHARMACEUTICALS INCORPORATED 447eeaee-1751-45cd-a8c4-c0b8d98d7f0b | Q4 | VERTEX PHARMACEUTICALS INCORPORATED | 40027242 | VERTEX PHARMACEUTICALS INCORPORATED | 2025 | fourth_quarter | PHA | Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families; Issues related to the NDAA S.Amdt.3841 BIOSECURE Act. | HOUSE OF REPRESENTATIVES,SENATE | 1110000 | 0 | 0 | 2026-01-13T17:05:29-05:00 | |
| 3483938 | KOUNTOUPES DENHAM CARR & REID, LLC 15ecf7ed-5ff5-47ce-a0f4-7fe6e8d17b29 | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | AMERICAN KRATOM ASSOCIATION | 2025 | fourth_quarter | PHA | Issues related to Food and Drug Administration regulatory and consumer access. Issues related to the Federal Kratom Consumer Protection Act. | HOUSE OF REPRESENTATIVES | 50000 | 0 | 0 | 2026-01-14T13:27:48-05:00 | |
| 3484113 | TSG ADVOCATES DC, LLC 159f3383-b669-48b7-93a5-32c0d6be3c85 | Q4 | TSG ADVOCATES DC, LLC | 401109292 | BELCHER PHARMACEUTICALS LLC | 2025 | fourth_quarter | PHA | Compounding pharmaceuticals | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-14T14:12:31-05:00 | |
| 3484168 | BURRELL INTERNATIONAL GROUP LLC ab53d48f-0923-4663-9e33-89b64148afde | Q4 | BURRELL INTERNATIONAL GROUP LLC | 401103483 | SHIONOGI INC. | 2025 | fourth_quarter | PHA | FY26 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2026-01-14T14:19:07-05:00 | |
| 3484205 | BURRELL INTERNATIONAL GROUP LLC 04a8f9a7-bbc6-4753-aedb-0f55a55970ab | Q4 | BURRELL INTERNATIONAL GROUP LLC | 401103483 | TONIX PHARMACEUTICALS HOLDING CORP. | 2025 | fourth_quarter | PHA | LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY26 Defense Appropriation for broad-spectrum antivirals, FY26 LHHS for Long COVID and cocaine overdose funding; Alternative to Pain Act and Chronic Pain coverage | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2026-01-14T14:25:23-05:00 | |
| 3484564 | SQUIRE PATTON BOGGS 8d363899-bfe2-4d15-9d5d-65ebac5efe27 | Q4 | SQUIRE PATTON BOGGS | 30906 | SK AMERICAS, INC. | 2025 | fourth_quarter | PHA | US pharmaceutical policies. | HOUSE OF REPRESENTATIVES,SENATE | 110000 | 0 | 0 | 2026-01-14T15:39:02-05:00 | |
| 3484621 | KOUNTOUPES DENHAM CARR & REID, LLC 7b1dda56-18b8-40d9-a65c-c5db46d25cea | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2025 | fourth_quarter | PHA | Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-14T15:57:46-05:00 | |
| 3484648 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 398dae9e-6021-4a17-bb52-dccd7c5f7be2 | Q4 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2025 | fourth_quarter | PHA | H.R.4958 - GRAS Act - The Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act - Fluoride and fluoridated water - Additive Ingredients in Drug Products - Over-the-Counter Tests - Pediatric Labeling | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 245484 | 0 | 0 | 2026-01-14T16:01:51-05:00 | |
| 3484652 | ARNOLD & PORTER KAYE SCHOLER LLP 594f84d7-26f0-46a1-901f-e569db8dce6c | Q4 | ARNOLD & PORTER KAYE SCHOLER LLP | 4301 | NOVO NORDISK, INC. | 2025 | fourth_quarter | PHA | Issues related to general compounding. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2026-01-14T16:02:04-05:00 | |
| 3484660 | KOUNTOUPES DENHAM CARR & REID, LLC e0e82268-f543-4428-af87-35038a7a78c6 | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2025 | fourth_quarter | PHA | General issues related to over-the-counter (OTC) pharmaceutical supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-14T16:04:11-05:00 | |
| 3484709 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 09a8ca86-5cf3-492d-b67d-4fdff932bfa8 | 4T | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | WALGREEN CO. | 2025 | fourth_quarter | PHA | Issues related to drug pricing reform and transparency Issues related to access and distribution of pharmaceutical products Issues related to Artificial Intelligence in healthcare Issues regarding immunization and vaccines | 50000 | 0 | 1 | 2026-01-14T16:16:59-05:00 | ||
| 3484739 | JEFFREY J. KIMBELL & ASSOCIATES, INC. 8058d2f4-e7a3-49b6-bd38-5a92126c5dc7 | 4T | JEFFREY J. KIMBELL & ASSOCIATES, INC. | 46038 | ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 2025 | fourth_quarter | PHA | Issues related to Domestic manufacturing; Issues related to supply chain resilience | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 1 | 2026-01-14T16:29:03-05:00 | |
| 3484851 | TIDAL BASIN ADVISORS, INC. eba37948-3e7a-41ac-9a1d-6f6d45ccc200 | 4T | TIDAL BASIN ADVISORS, INC. | 401108081 | YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOW | 2025 | fourth_quarter | PHA | The DRUG Act, H.R.2214 (generally, no specific provisions) The DOC Access Act, H.R.1521 (generally, no specific provisions) The ACCESS Act, bill number not yet available (generally, no specific provisions) The ORPHAN Cures Act, H.R.946/S.1862 (generally, no specific provisions) | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2026-01-14T18:14:32-05:00 | ||
| 3484975 | THE KPM GROUP DC LLC 348b37d6-9bf8-4f22-a1d5-dbd868546c57 | Q4 | THE KPM GROUP DC LLC | 401105372 | PRAXIS PRECISION MEDICINES | 2025 | fourth_quarter | PHA | H.R.1262/S.932, Give Kids a Chance Act H.R.1509/S.752, Accelerating Kids Access to Care Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2026-01-14T21:39:13-05:00 | |
| 3484976 | THE KPM GROUP DC LLC 9b51f119-b75d-45fa-a7d2-7847f1182f7d | Q4 | THE KPM GROUP DC LLC | 401105372 | REZOLUTE | 2025 | fourth_quarter | PHA | S.4426, Promising Pathway Act 2.0 (118th Congress) | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-14T21:40:37-05:00 | |
| 3484982 | THE KPM GROUP DC LLC 3808d68d-7990-426d-8fbd-d6f8409613ca | Q4 | THE KPM GROUP DC LLC | 401105372 | THE HS COALITION | 2025 | fourth_quarter | PHA | S.864, Help Ensure Lower Patient (HELP) Copays Act H. Res 484, Expressing support for the recognition of "Hidradenitis Suppurativa Awareness Week" H.R. 5509 Safe Step Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-14T21:47:19-05:00 | |
| 3485108 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 2cc5ab41-493c-4a75-a461-2f2cd25681df | Q4 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) | 401105192 | CVS HEALTH | 2025 | fourth_quarter | PHA | Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-15T08:41:45-05:00 | |
| 3485312 | BALLARD PARTNERS 857fefd2-5ebe-4b1d-a9e4-3cc55f140a6a | Q4 | BALLARD PARTNERS | 401104288 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2025 | fourth_quarter | PHA | Lower healthcare costs, pharmacy coverage and reimbursement issues, (does not include any PBM issues). | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS) | 90000 | 0 | 0 | 2026-01-15T09:58:18-05:00 | |
| 3485547 | THE HARPLE GROUP, LLC f47e8740-6d83-4b9e-88f9-b49eb3d1b385 | Q4 | THE HARPLE GROUP, LLC | 401108916 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA) | 2025 | fourth_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, and prescription drug pricing Pharmacy Benefit Manager Transparency Act of 2023; Prescription Pricing for the People Act of 2023; HELP Copays Act; Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); Lowering Drug Costs for American Families Act; Protecting Patients Against PBM Abuses Act; The Drug Act; Lower Costs, More Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-15T10:52:20-05:00 | |
| 3485641 | THORSEN FRENCH ADVOCACY LLC 991c6671-7632-4dd6-8a30-dd2949b3f858 | Q4 | THORSEN FRENCH ADVOCACY LLC | 400599826 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 | fourth_quarter | PHA | Issues realted to anti-competitive tactics in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2026-01-15T11:11:30-05:00 | |
| 3485653 | KOUNTOUPES DENHAM CARR & REID, LLC 8fb4eef6-cf55-40b1-81d6-e2621c044670 | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2025 | fourth_quarter | PHA | Issues related to pharmaceutical supply chains and patient access. Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act and S.2426, Equitable Community Access to Pharmacist Services Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-15T11:13:00-05:00 | |
| 3486022 | BROWNSTEIN HYATT FARBER SCHRECK, LLP f7e890ef-ec07-42e5-ab37-79b907e2c8f1 | Q4 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | CENCORA, INC. | 2025 | fourth_quarter | PHA | Recognizing pharmacists as providers within Medicare; The Equitable Introduction of Community Access to Pharmacist Services Act Medicare reimbursement. | 60000 | 0 | 0 | 2026-01-15T12:37:28-05:00 | ||
| 3486379 | KOUNTOUPES DENHAM CARR & REID, LLC cb61ea2f-6999-40b8-a826-a796e2b290ab | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GS1 US | 2025 | fourth_quarter | PHA | Issues related to the pharmaceutical supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-15T13:48:38-05:00 | |
| 3486585 | COREWELL HEALTH 69613d58-4c7f-43a2-a827-8b798430d90e | Q4 | COREWELL HEALTH | 298455 | COREWELL HEALTH | 2025 | fourth_quarter | PHA | 340B - Reforms to protect the integrity of the program. PBM Reform/Oversight. Transparency and high costs associated with prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 180000 | 0 | 0 | 2026-01-15T14:23:09-05:00 | |
| 3486698 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) ca6fe7df-db8f-453b-a7e1-691fe9c324ea | Q4 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2025 | fourth_quarter | PHA | Opioid Abuse - General issues related to access to medication assisted treatment General Issues Related to report language regarding paper inserts | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 596609 | 0 | 0 | 2026-01-15T14:39:36-05:00 | |
| 3486995 | ELI LILLY AND COMPANY 06ea6567-0738-42bf-82b3-e31f08e06dee | Q4 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2025 | fourth_quarter | PHA | Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act | HOUSE OF REPRESENTATIVES,SENATE | 2200000 | 0 | 0 | 2026-01-15T15:29:14-05:00 | |
| 3487011 | PUBLIC CITIZEN 33abe508-df00-4fe7-a8b4-fa62c8630dba | Q4 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2025 | fourth_quarter | PHA | prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions. | HOUSE OF REPRESENTATIVES,SENATE | 73000 | 0 | 0 | 2026-01-15T15:34:21-05:00 | |
| 3487277 | BROWNSTEIN HYATT FARBER SCHRECK, LLP c599c9cc-6b06-4640-b0ac-3c4c489477fc | Q4 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS | 2025 | fourth_quarter | PHA | issues related to pharmaceutical manufacturing Tax and trade policy affecting the pharmaceutical industry | Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 80000 | 0 | 0 | 2026-01-15T16:36:05-05:00 | |
| 3487456 | MR. DAVID FRIEDMAN ef7cebea-4958-4f18-b598-dcc553d9c8b0 | Q4 | MR. DAVID FRIEDMAN | 401110165 | TEVA PHARMACEUTICALS USA, INC. | 2025 | fourth_quarter | PHA | Issues related to strengthening the domestic supply and manufacture of essential medicines. | Commerce, Dept of (DOC) | 200000 | 0 | 0 | 2026-01-15T17:32:03-05:00 | |
| 3487562 | TAUZIN CONSULTANTS, LLC c3e87cfa-25bb-4ef8-aef3-d08952d4be62 | Q4 | TAUZIN CONSULTANTS, LLC | 400671007 | RAZORMETRICS | 2025 | fourth_quarter | PHA | Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2026-01-15T18:41:22-05:00 | |
| 3487667 | BALLARD PARTNERS 3b927405-e09f-422f-b6ef-4a3dddd74d29 | Q4 | BALLARD PARTNERS | 401104288 | PUBLIX SUPER MARKETS, INC. | 2025 | fourth_quarter | PHA | Healthcare policy reforms; Healthcare and budget reconciliation. | HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2026-01-15T20:29:06-05:00 | |
| 3487695 | BALLARD PARTNERS 436aa0eb-096d-4d03-85a6-ff0702bec9e0 | Q4 | BALLARD PARTNERS | 401104288 | RIO BIOPHARMACEUTICALS, INC. | 2025 | fourth_quarter | PHA | Assisting with applications before the Food & Drug Administration for generic pharmaceutical approvals. | Commerce, Dept of (DOC),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 150000 | 0 | 0 | 2026-01-15T20:51:17-05:00 | |
| 3487935 | PORT SIDE STRATEGIES, LLC 9147a74d-8707-474d-a404-c4d1ebf461ed | Q4 | PORT SIDE STRATEGIES, LLC | 401105394 | SOCIAL SECURITY WORKS | 2025 | fourth_quarter | PHA | Affordable Insulin Now Act - in support. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2026-01-16T09:40:22-05:00 | |
| 3487951 | PORT SIDE STRATEGIES, LLC 9ddb57bb-90c7-400a-bc9f-b362fc62ec7d | Q4 | PORT SIDE STRATEGIES, LLC | 401105394 | CENTER FOR HEALTH AND DEMOCRACY | 2025 | fourth_quarter | PHA | Issues related to pharmacy benefit managers. H.R.9096 - Pharmacists Fight Back Act - in support. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2026-01-16T09:42:27-05:00 | |
| 3488085 | BALLARD PARTNERS 2380b9a1-3cb6-410d-b526-c56c965bc539 | Q4 | BALLARD PARTNERS | 401104288 | SENIOR CARE PHARMACY, INC. | 2025 | fourth_quarter | PHA | Senior prescription affordability. | Health & Human Services, Dept of (HHS) | 40000 | 0 | 0 | 2026-01-16T10:10:48-05:00 | |
| 3488144 | BALLARD PARTNERS 7e40d406-099b-4927-93bf-7f4951c6f1a6 | Q4 | BALLARD PARTNERS | 401104288 | THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS) | 2025 | fourth_quarter | PHA | 340B Drug Discount Program. | Health & Human Services, Dept of (HHS) | 50000 | 0 | 0 | 2026-01-16T10:22:07-05:00 | |
| 3488236 | MARSHALL & POPP, LLC e688bb5b-af24-40f2-b0e3-6849bec9a46e | Q4 | MARSHALL & POPP, LLC | 401105121 | ABBVIE INC. | 2025 | fourth_quarter | PHA | Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 60000 | 0 | 0 | 2026-01-16T10:38:24-05:00 | |
| 3488243 | MARSHALL & POPP, LLC c4607382-7ebc-41f7-8187-b18932b52395 | Q4 | MARSHALL & POPP, LLC | 401105121 | AMGEN USA INC. | 2025 | fourth_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-16T10:40:37-05:00 | |
| 3488246 | MARSHALL & POPP, LLC 7d0f27be-6c7f-4ec1-90cb-e5edb4a8eb36 | Q4 | MARSHALL & POPP, LLC | 401105121 | BRIDGEBIO PHARMA | 2025 | fourth_quarter | PHA | Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-16T10:41:01-05:00 | |
| 3488251 | MARSHALL & POPP, LLC 16ca5dd8-0fdb-4621-a443-49eedd19fc02 | Q4 | MARSHALL & POPP, LLC | 401105121 | CSL BEHRING | 2025 | fourth_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act). | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-16T10:42:23-05:00 | |
| 3488256 | MARSHALL & POPP, LLC 57a062f9-ed52-4cba-9307-4b6179ac8e82 | Q4 | MARSHALL & POPP, LLC | 401105121 | ELI LILLY AND COMPANY | 2025 | fourth_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-16T10:42:51-05:00 | |
| 3488264 | MARSHALL & POPP, LLC 9393c4cf-8d41-4273-a603-4c5bf3a7120a | Q4 | MARSHALL & POPP, LLC | 401105121 | GENENTECH, INC. | 2025 | fourth_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-16T10:45:24-05:00 | |
| 3488289 | MARSHALL & POPP, LLC 646288ed-7a9f-4bb4-b19d-6f988be58de0 | Q4 | MARSHALL & POPP, LLC | 401105121 | PFIZER, INC. | 2025 | fourth_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-16T10:48:47-05:00 | |
| 3488294 | MARSHALL & POPP, LLC 81d2d0e9-3773-4f28-baef-7ba1efb1752a | Q4 | MARSHALL & POPP, LLC | 401105121 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 | fourth_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2026-01-16T10:49:32-05:00 | |
| 3488323 | MARSHALL & POPP, LLC 22f6263d-a0f7-4754-8a52-0703ab7ecca6 | Q4 | MARSHALL & POPP, LLC | 401105121 | SANOFI U.S. SERVICES, INC. | 2025 | fourth_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-16T10:57:34-05:00 | |
| 3488442 | ASCENSION HEALTH ALLIANCE D/B/A ASCENSION c938ef5a-c262-4966-9d79-fa73b185a6cc | Q4 | ASCENSION HEALTH ALLIANCE D/B/A ASCENSION | 401105339 | ASCENSION HEALTH ALLIANCE D/B/A ASCENSION | 2025 | fourth_quarter | PHA | 340B Program; Issues related to affordable prescription drugs; Equitable Community Access to Pharmacy Services Act; issues related to preventing and mitigating drug shortages; | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 485000 | 0 | 0 | 2026-01-16T11:22:24-05:00 | |
| 3488475 | ISEMAN & ASSOCIATES LLC ee4b8466-942a-40ed-81c2-63bef659143b | Q4 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2025 | fourth_quarter | PHA | Monitoring biotech legislation | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2026-01-16T11:25:32-05:00 | ||
| 3488540 | KOUNTOUPES DENHAM CARR & REID, LLC 25e60ea0-90f2-4ea7-9713-6c22c34687d1 | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | MCKESSON CORPORATION | 2025 | fourth_quarter | PHA | Issues related to H.R. 3164, ensuring Community Access to Pharmacist Services Act. and S.2426, Equitable Community Access to Pharmacist Services Act. | 60000 | 0 | 0 | 2026-01-16T11:37:40-05:00 | ||
| 3488635 | POLARIS GOVERNMENT RELATIONS, LLC d75b5231-c971-4908-aa0e-7212cc9e81d1 | Q4 | POLARIS GOVERNMENT RELATIONS, LLC | 307730 | CIGNA CORPORATION | 2025 | fourth_quarter | PHA | Drug pricing and issues facing the pharmacy benefit manager industry generally | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2026-01-16T11:56:09-05:00 | |
| 3488765 | MEHLMAN CONSULTING, INC. 401ee552-0bb5-44b4-8573-5a32ee7fc7a0 | Q4 | MEHLMAN CONSULTING, INC. | 284950 | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | 2025 | fourth_quarter | PHA | Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 1067 - Ensuring Timely Access to Generics Act; S. 2630 - REMEDY Act; H.R.1262 - Mikaela Naylon Give Kids a Chance Act. | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2026-01-16T12:09:15-05:00 | |
| 3489086 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION d6cd4606-7eac-4a0c-93a7-685b94feb79b | Q4 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2025 | fourth_quarter | PHA | Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing. | Bureau of Industry and Security (BIS),Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-16T12:43:30-05:00 | |
| 3489221 | PENN AVENUE PARTNERS 6a6e387b-6fce-4dbb-9fa1-cd3f717c0828 | Q4 | PENN AVENUE PARTNERS | 400918672 | UNITEDHEALTH GROUP, INC. | 2025 | fourth_quarter | PHA | Pharmacy benefit related issues. | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2026-01-16T13:05:53-05:00 | |
| 3489355 | NELSON MULLINS RILEY & SCARBOROUGH 4958b5b5-3fea-4318-a0e1-2391481a5d2f | Q4 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2025 | fourth_quarter | PHA | 340B Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2026-01-16T13:22:42-05:00 | |
| 3489646 | DA VINCI GROUP 248663cc-1a45-4926-b172-cd50695b5a86 | Q4 | DA VINCI GROUP | 11548 | BOESEN & SNOW, LLC | 2025 | fourth_quarter | PHA | Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2026-01-16T14:11:56-05:00 | |
| 3489658 | DA VINCI GROUP 2cc45706-168e-4d20-bff1-3041f485d78b | Q4 | DA VINCI GROUP | 11548 | PROCARE, INC. | 2025 | fourth_quarter | PHA | Issues related to PBM reform. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2026-01-16T14:15:26-05:00 | |
| 3489834 | E3 STRATEGIC CONSULTING GROUP 95bf23ef-8529-45b1-8fd7-dc82b57da733 | Q4 | E3 STRATEGIC CONSULTING GROUP | 401104104 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2025 | fourth_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;" S. 3345 - "PBM Price Transparency and Accountability Act." | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-16T14:39:06-05:00 | |
| 3489979 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 23560269-e700-4b9a-873b-23c76a0203bb | Q4 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | PIERRE FABRE PHARMACEUTICALS INC. | 2025 | fourth_quarter | PHA | Issues related to drug development, rare disease innovations, and issues impacting the pharmaceutical industry. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2026-01-16T14:56:51-05:00 | |
| 3490012 | DLA PIPER LLP (US) d365c0da-d411-4053-be82-1ec4bf5d08f5 | Q4 | DLA PIPER LLP (US) | 76855 | XEROX HOLDINGS CORPORATION (FORMERLY LEXMARK INTERNATIONAL, INC.) | 2025 | fourth_quarter | PHA | Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-16T15:00:48-05:00 | |
| 3490077 | BOLD STRATEGIES, LLC 4e394c93-269b-478e-89ad-5c4a48734be8 | Q4 | BOLD STRATEGIES, LLC | 401104653 | MORRIS & DICKSON CO., LLC | 2025 | fourth_quarter | PHA | Prescription drug issues generally. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2026-01-16T15:05:56-05:00 | |
| 3490152 | DLA PIPER LLP (US) 8f3a5f6e-7854-4522-968c-2e8a571aefd1 | Q4 | DLA PIPER LLP (US) | 76855 | BIOTECHNOLOGY INNOVATION ORGANIZATION | 2025 | fourth_quarter | PHA | 340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2026-01-16T15:13:09-05:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);